Vertex Pharmaceuticals Unrealized Losses on Investments (Before Tax) decreased by 33.3% to $800.00K in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 33.3%, from $600.00K to $800.00K. This is a positive signal — lower values indicate better performance for this metric.
An increase suggests declining market value of the firm's investment holdings, which may negatively impact book value and regulatory capital.
This metric tracks the total unrealized losses on investment securities, primarily available-for-sale assets, before acc...
Standard disclosure for financial institutions to show the impact of market volatility on investment portfolios.
unrealized_losses_on_investments| Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|
| Value | $16.10M | $24.20M | $19.10M | $23.40M | $600.00K | $2.20M | $1.20M | $800.00K |
| QoQ Change | — | +50.3% | -21.1% | +22.5% | -97.4% | +266.7% | -45.5% | -33.3% |
| YoY Change | — | — | — | +45.3% | -97.5% | -88.5% | -94.9% | +33.3% |
We use cookies for analytics. See our Privacy and Cookie Policy.